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Abstract
17q23 is a frequent site of gene amplification in breast
cancer. Several lines of evidence suggest the presence
of multiple amplicons on 17q23. To characterize distinct
amplicons on 17q23 and localize putative oncogenes,
we screened genes and expressed sequence tags
(ESTs) in existing physical and radiation hybrid maps
for amplification and overexpression in breast cancer
cell lines by semiquantitative duplex PCR, semiquanti-
tative duplex RT-PCR, Southern blot, and Northern blot
analyses. We identified two distinct amplicons on
17q23, one including TBX2 and another proximal region
including RPS6KB1 (PS6K ) and MUL. In addition to
these previously reported overexpressed genes, we
also identified amplification and overexpression of
additional uncharacterized genes and ESTs, some of
which suggest potential oncogenic activity. In conclu-
sion, we have further defined two distinct regions of
gene amplification and overexpression on 17q23 with
identification of new potential oncogene candidates.
Based on the amplification and overexpression patterns
of known and as of yet unrecognized genes on 17q23, it
is likely that some of these genes mapping to the
discrete amplicons function as oncogenes and contrib-
ute to tumor progression in breast cancer cells.
Neoplasia (2001) 3, 521–526.
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Introduction
Gene amplification is a common mechanism through which
protooncogenes are overexpressed and contribute to tumor
progression. Comparative genomic hybridization (CGH) and
fluorescent in situ hybridization studies (FISH) have
revealed several regions of amplification on chromosome
17q in breast cancer [1,2 ]. One well -known amplicon on
17q21 is associated with overexpression of the ERBB2
(HER-2/NEU) protooncogene. Other regions of 17q ampli-
fications distal to and excluding the ERBB2 (HER-2/NEU)
region have also been reported [3,4 ]. 17q23 is of particular
interest because it is a gene-rich region and amplification of
17q23 has been frequently described in breast cancer.
Amplification and overexpression of 17q23 genes (RAD51C,
RPS6KB1 (PS6K ), NACA, PAT1, SIGMA1B, and TBX2 )
have been reported in breast cancer [4–6]. Independently,
Rouillard et al. [7 ] recently identified a discrete 228-kb
amplified region that contains 200 copies of the TBX2 gene in
a primary breast tumor sample by using a novel virtual
genome scanning method to detect regions of amplification,
deletion, or aberrant methylation. Recent functional studies of
TBX2 demonstrate that it acts as a potent immortalizing gene
by downregulating p19ARF [8 ]. Another interesting gene that
is amplified and overexpressed on 17q23 is RPS6KB1, which
is involved in G1-S progression [9,10]. Thus, independent
lines of evidence suggest that 17q23 has several strong
functional candidates as amplification targets.
To further characterize and to better define the boundaries
of 17q23 amplicon(s) and find other potential candidate
oncogenes, we extended the screen of the expressed
sequence tags (ESTs) and known genes in physical and
radiation hybrid maps on 17q23 for amplification and over-
expression in 24 breast cancer cell lines. Thus, in this study
we delineated two distinct amplicons on 17q23 including
possible targets: MUL, RPS6KB1, and TBX2. Moreover, we
identified additional potential targets of gene amplification
and overexpression in these amplicons that may serve as
oncogenes in the malignant progression of some breast
tumors.
Materials and Methods
Cancer Cell Lines and Tumor DNA
All breast cancer cell lines, except SUM and human
papilloma virus immortalized nontumorigenic mammary cell
lines (HPV), were obtained from American Type Culture
Collection (ATCC, Manassas, VA) and grown under recom-
mended conditions (http: //www.atcc.org/ ). SUM and HPV
lines were developed and provided by S. P. Ethier at The
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University of Michigan Comprehensive Cancer Center [11–
14]. Information about these cell lines is available at
www.cancer.med.umich.edu/breast_cell /clines/clines.html.
Primary breast tumor DNA (T-200) has a well -defined
228-kb amplicon including TBX2 on 17q23 [7] and was used
as a positive control for amplification in our experiments (use
of anonymous human samples was approved by the
University of Michigan Institutional Review Board).
DNA and RNA Isolation
Genomic DNA was isolated from breast cell lines by
treatment with 200 g/ml of proteinase K, 1% SDS, 500 mM
Tris, 20 mM EDTA, 10 mM NaCl pH 9.0, and extracted with
1:1 phenol /chloroform using standard methods. Ethanol -
precipitated DNA was resuspended in 1TE (0.5 M EDTA,
1M Tris, pH 8.0). Total RNA was isolated from cell lines
grown to 70% confluency after cell lysis using Trizol reagent
according to manufacturer’s instructions (Gibco BRL, Rock-
ville, MD) and resuspended in nuclease- free water.
Semiquantitative Duplex PCR
Primers for the ESTs and genes on 17q23 in physical
(Human Genome Sequencing, http: //www.ncbi.nlm.nih.
gov/genome/seq) and radiation hybrid maps (Gene-
Map’99, http: //www.ncbi.nlm.nih.gov /genemap99) were
designed by using the Primer program (Whitehead Institute
for Biomedical Research, Version 0.5) (Table 1). Genes and
ESTs were coamplified in duplex PCR reactions using
titrated primer concentrations of an internal control, glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH ) and/or
thymidine kinase 1 (TK1 ) to generate equal amounts of PCR
products. The exponential phase of amplification was
determined for duplexed primer sets by analyzing PCR
products after completion of cycles 22, 24, 26, 28, 30, 32,
and 35. The products were resolved and analyzed on
ethidium bromide–stained 3% agarose gel (Figure 1A ).
Band intensities were quantified by densitometry (Alpha
Innotech IS-1000 Digital Imaging System, version 2.00).
The exponential increase range of amplification was
determined by plotting the log (peak area) versus PCR
cycle number graph (Figure 1B ). DNA samples from cell
lines and the primary breast tumor sample were coamplified
with the duplexed primers using the number of cycles that is
in the exponential range of amplification curve. PCR
products were quantified by densitometry. The ratios of
amplification between gene products and controls (GAPDH
and/or TK1 ) were compared to the ratio calculated for
normal human genomic DNA samples.
Semiquantitative Duplex RT-PCR
RNA was treated with RNase- free DNase1 (Boeh-
ringer Mannheim, Indianapolis, IN) to eliminate DNA
Table 1. Designed Primers for ESTs and Genes Mapped to 17q23.
STS /Gene Name RH Size ( bp ) Sense Primer Antisense Primer
SGC34835 GB4, G3 148 AGAGTAGCACAAAAGTCCCAGA TGGGAGAGATGATGTGCCTG
stsG22003 GB4 282 TTGTTTATTTTCCTCCCAAGC TGGGGATTTCTTGGTTTGTG
RPS6KB1 G3 129 GTCTTTGCTTCCATTTTGCT TCTGATTGTGTTGAAGAAGGG
SHGC-24306 GB4, G3 221 ACTAAATGCCCTCAAAGCCC TCTGTGGGATTTCATCTTAGGG
stSG52524 GB4 196 CTACTCATCCAAGGGAGGTCA GGTTGTGCTTCCTTACTGACTG
TBX2 GB4 188 GGTGCAGACAGACAGTGCGT AGGCCAGTAGGTGACCCATG
FB10A2 GB4 153 ATGACAACTCGCACCCCAC GCCAGAGGGATAGGTGGAGT
Zs29c11.r1 – 337 TTGCTTCCATTTTGAGACATT AGCCAGGTGTAGAGCCCAAG
stsG46879 GB4 91 TGCTGTTGGTACTGGTATTGTC TCCACTTTAACAAAGCAGCC
Other primer sequences that are not in this list are from databases ( http: //www.ncbi.nlm.nih.gov / genemap99 / ). PCR conditions are available on request.
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Figure 1. Semiquantitative duplex PCR optimization of SGC31117 and
GAPDH primers. (A ) Exponential range of amplification was detected by
analyzing PCR products for duplexed primer sets after completion of cycles
22, 24, 26, 28, 30, 32, and 35. The products were resolved on an ethidium
bromide–stained 3% agarose gel. Band intensities were quantified by
densitometry. (B ) Log (peak area ) versus cycle number graph reveals the
linear range of amplification. For these primers, 24 cycles were chosen for
semiquantitative duplex PCR screening of breast cancer cell lines for
amplification.
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contamination. Five micrograms RNA was used to
generate cDNA with Oligo(dT) primers using the Super-
script Preamplification system (Gibco BRL). Duplexing
and quantification was done as described above for the
semiquantitative duplex PCR. The ratios of amplification
were compared to human papilloma virus immortalized
nontumorigenic mammary cell lines (HPV11-21 and/or
HPV11-6).
Southern Blot Analysis
Five micrograms of genomic DNA from each cell line
was digested to completion with excess restriction endo-
nuclease MspI under standard reaction conditions (Gibco
BRL). Digested DNA was separated on 0.9% agarose gels
in 1TBE and transferred to Hybond N+ membranes
(Amersham, Piscataway, NJ) in 20SSC. Membranes
were fixed in 0.4 N NaOH and rinsed in 5SSC. Probes
were generated by random priming [15] with [ - 32P]dCTP
and preblocked with 50 g human Cot1-DNA at 608C to
mask any repetitive elements. Hybridizations were per-
formed overnight in 0.5 M NaH2PO4, 1 mM EDTA, 7%
SDS buffer [16]. After hybridization, blots were washed at
608C in 2SSC, 0.1% SDS and exposed to Kodak XAR-5
film to obtain various exposures. Control probes GAPDH
(407 bp, F: GGGAGCCAAAAGGGTCATCA, R:TTTCTA-
GACGGCAGGTCAGGT) or  -actin (340bp, F: GGCACC-
ACACCTTCTACAATG R: CTCCTTAATGTCACGCACGA)
were amplified from normal human genomic DNA.
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BT20 - - - - - - - - - - - - - - - - - -
BT474 - - - - - + + + + + + + + - - - - - - - -
BT549 - - - - - - - - - - - - - - - - - -
CAL51 - - - - - - - - - - - - - - - - - -
DU4475 - - - - - - - - - - - - - - - - - -
Hs578T - - - - - - - - - - - - - - - - - -
MCF7 - - - - - + + - + + + + + + + + + + + + + + + + + + + +
MDA-MB231 - - - - - - - - - - - - - - - - - -
MDA-MB361 - - - - - + + S S + - + - + + S + - -
MDA-MB435 - - - - - - - - - - - - - - - - - -
MDA-MB468 - - - - - - - - - - - - - - - - - -
SK-BR3 - - - - - - - - - - - - - - - - - -
SUM-149 - - - - - - - - - - - - - - - - - +
SUM-159 - - - - - - - - - - - - - - - - - -
SUM-185 - - - - - - - - - - - - - - - - - -
SUM-225 - - - - - - - - - - + - - - - - - -
SUM-1315 - - - - - - - - - - - - - - - - - -
MCF10 - - - - - - - - - - - - - - - - - -
MDA-MB157 - - - - - - + - - - - - - - - - - -
SUM-44 - - - - - - - - - - - - - - - - - -
SUM-52 - - - - - - - - - - - + + - + + + + + - -
ZR-75-1 - - - - - - - - - - - - - - - - - -
SUM-102 - - - - - - - - - - - - - - - - - -
T-47D - - - - - - - - - - - - - - - - - -
T-200 - - - - - - - + + + - + - + + + + + + + + + - +
Figure 2. Amplification and overexpression patterns of ESTs and genes in 24 breast cancer cell lines and one primary breast tumor sample (T -200 ) ( detected by
semiquantitative duplex PCR and semiquantitative duplex RT -PCR except the boxes marked as ‘‘S’’ that are detected only by Southern blot analysis ). Markers in
the databases are listed proximal to distal on 17q23 based on the physical map of Monni et al. [ 17 ]. The screened contigs in the databases are shown at the top of
corresponding EST /gene names. Plus sign ( + ) indicates the level of amplification; + : 2 to 2.5 - fold, + + : 2.5 to 5 - fold, + + + : more than 5 - fold, S: amplification
detected only by Southern analysis. Light gray box (& ) indicates overexpression 1.0 to 2.5 times. Darker gray box (& ) indicates overexpression more than 2.5
times. Minus sign (  ) indicates no amplification and no overexpression. Gap between the contigs is marked with a question mark.
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Northern Blot Analysis
Ten micrograms of total RNA sample was fractionated on
1.5% denaturing agarose gels and transferred to HybondL
membranes (Amersham) in 20SSC. Hybridization was
performed as described previously. The same control probes
were used as described in Southern blot analysis. Ethidium
bromide staining of ribosomal RNA on agarose gels was
consistent with GAPDH hybridization patterns as a loading
control (data not shown).
Results
To further delineate the 17q23 amplicon(s), we used
semiquantitative duplex PCR as an initial screening tool to
identify amplifications in 24 breast cancer cell lines and in
one previously described 17q23 amplification positive
primary breast tumor sample (T-200, see Materials and
Methods section). Primers for genes and ESTs that
mapped to 17q23 on physical [17] and radiation hybrid
maps (http: //www.ncbi.nlm.nih.gov/genemap99/ ) were
duplexed with the control primers. The linear range of
amplification was detected for each reaction (Figure 1 ).
The 17q23 amplification positive primary breast tumor
sample (T-200) and MCF7 cell line have been previously
shown to have amplification and overexpression of TBX2
by semiquantitative duplex PCR [7]. In this study, we
subsequently detected the same region to be amplified in
SUM-52 and MDA-MB361 cell lines, as well. We detected
amplification of TBX2 in SUM-52 (5- fold ) by semiquanti-
tative duplex PCR and in MDA-MB361 (2- fold) by
Southern blot analysis (Figure 2 ).
TBX2 maps to contig NT_001445 (http: //www.ncbi.
nlm.nih.gov/genome/seq/ ) that contains six overlapping
BAC and PAC clones. We screened seven ESTs for
amplification and overexpression in this contig. In addition
to TBX2, FLJ20128, a protein of unknown function, was
also significantly amplified and overexpressed in the
primary breast tumor sample ( >20- fold and 4.5- fold ),
in SUM-52 (4- fold, 1.6- fold), in MDA-MB361 (2.5- fold,
4.5- fold), and in MCF7 (3.4- fold, 10- fold) compared to
normal human genomic DNA and HPV immortalized
nontumorigenic mammary cell line (Figure 3 ). An EST,
T02811.1, was also amplified and overexpressed in T-
200 ( >20- fold, 5.5- fold ), in SUM-52 (2.5- fold, 5.5- fold ),
MCF7 (2.5- fold, 2.9- fold), and in MDA-MB361 (3.5- fold,
1.2- fold). No conserved domains or homology to known
genes for FLJ20128 and T02811.1 was found in
comprehensive database searches, ExPASy Proteomics
tools (Swiss Institute of Bioinformatics), [18] and RPS-
BLAST [19].
The more proximal (stSG8656) and distal EST markers
(stSG39856) that flank the small TBX2 amplicon did not
show any amplification in SUM-52 and MDA-MB361. Lack
of amplification was also in agreement with semiquantitative
RT-PCR results indicating no overexpression for T-200,
MDA-MB361, and SUM-52 for those flanking EST markers.
Interestingly, however, MCF7 had a region of amplification
and overexpression larger than the amplicon detected in
MDA-MB361, SUM-52, and the primary breast tumor
sample (T-200). The presence of the same amplicon
boundaries for SUM-52, MDA-MB361, and the amplification
positive primary breast tumor sample (T-200) led us to
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Figure 3. Amplification and overexpression of a gene (FLJ20128 ) that encodes a protein of unknown function distal to TBX2. (A ) Semiquantitative duplex PCR for
FLJ20128. Amplified samples are shown with asterisks. The ratios of amplification compared to the normal human control (C ) is MCF7: 3.4, MDA-MB361: 2.5,
SUM-52: 4, and T -200: more than 20 - folds of amplification ( exact ratio was not measured due to high amplification and saturation ). (B ) Semiquantitative duplex
RT -PCR for FLJ20128. The ratios of overexpression compared to HPV11 -21 is MCF7: 10, MDA-MB361: 4.5, SUM-52: 1.6, and T -200: 4.5 - folds. HPV11 -21 is a
human papilloma virus immortalized nontumorigenic mammary cell line and is used as a control.
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further evaluate the presence of other discrete amplicons in
the region.
Because there are no overlapping contigs with
NT_001445 in the databases (http: //www.ncbi.nlm.nih.
gov/genome/seq/ ), we screened the genes and ESTs
mapping to contigs that are proximal to NT_001445, which
includes contigs: NT_000833, NT_000853, and
NT_000854. NT_000833 contains RPS6KB1, which is
amplified in MCF7 independent of ERBB2 amplicon, in
BT474, and in MDA-MB361 cell lines [6]. Our results
confirmed this pattern as well as amplification and over-
expression of flanking ESTs and MUL (Mulibrey nanism).
MUL was 2.5- fold overexpressed in MCF7, 2- fold in
BT474, and 1.7- fold in MDA-MB361 as detected by
semiquantitative duplex RT-PCR (Figure 2 ). Northern blot
analysis also confirmed the overexpression patterns in
these cell lines (Figure 4 ). The same region was also
amplified in the primary breast tumor (T-200) but no
overexpression was detected in T-200. Interestingly,
BT474 demonstrated 2.9- fold amplification for the EST
stSG22003 but no overexpression was detected by semi-
quantitative duplex RT-PCR, whereas 2.5- fold overex-
pression was detected for the EST stsG52524, which had
no genomic amplification. Despite the lack of genomic
amplification in BT474, overexpression of the EST
stsG52524 was consistent with the low- level amplification
and overexpression in primary breast tumor T-200 (2-
fold, 4- fold). Additional proximal ESTs and genes
(SGC31117, COIL, stSG42776, SGC34835, and PNUTL2 )
did not show any amplification by PCR in any of the 24
cell lines tested.
Discussion
In this study, we screened EST and gene-derived PCR
markers and probes mapping to 17q23 contigs, NT_000-
833 (244179bp), NT_000854 (99411bp), NT_000853
(216981bp), and NT_001445 (874273bp) to determine
the oncogenic targets and to refine the boundaries of
17q23 amplicon(s) in breast cancer cells. We identified
two distinct amplification regions within 17q23. MCF7
showed a more continuous amplification and overexpres-
sion pattern for ESTs and genes in NT_001445 and
NT_000833, covering both proximal and distal regions,
whereas BT474 had significant amplification and over-
expression localized to NT_000833 and SUM-52 localized
to NT_001445. Monni et al. [17] reported a continuous
region of amplification in BT474 and two distinct regions in
MCF7 on 17q23. Although our results also confirm lack of
amplification for stSG33700 in MCF7 cells, our data
suggest that this EST is, in fact, overexpressed three-
fold. This supports the growing body of evidence that the
degree of amplification and overexpression might not
always be linearly related. Usually, a high level of
amplification is associated with overexpression but our
data suggest that some genes might be grossly overex-
pressed even though they are not significantly amplified
suggesting that other factors rather than increased gene
copy number are associated with overexpression. Similarly,
2.5- fold overexpression was detected for the EST
stsG52524 in BT474 whereas no significant genomic
amplification was detected. According to our data, the
critical and significant region of amplification for BT474 is
only localized to ESTs and genes mapping to NT_000833
as we did not detect significant amplification or over-
expression in ESTs and genes mapping to NT_001445 in
BT474 by PCR, Southern, and Northern analyses. It is
possible that BT474 has very low amplification localized to
NT_001445 as 1.2- fold amplification was detected for
TBX2 in BT474 previously [1 ], but the lack of significant
overexpression suggests that the genes in this distal region
may not be potent oncogenes in BT474 cells. Thus, our
results show that the critical amplicon for BT474 resides in
the proximal region whereas MCF7 has amplification and
overexpression in both proximal and distal regions. MDA-
MB361 had a more discontinuous pattern of amplification
throughout both of the proximal and distal amplicons and
SUM-52 had low- level amplification and overexpression
only at the distal region including TBX2. We did not detect
amplification in the proximal region in MDA-MB361 cells
by PCR alone but Southern blot analysis revealed around
two- fold amplification of ESTs tested for this cell line. In
spite of the ease of semiquantitative duplex PCR as an
initial screening tool, our studies support that Southern blot
analysis should be used to confirm PCR results in cases
where amplification is no more than 2- to 2.5- fold. In other
cases, Southern and Northern blot results were in agree-
ment with PCR results.
The significant region of amplification for the primary
breast tumor sample resides only in the distal, several
hundred kilobases region in NT_001445 covering a hypo-
thetical protein (FLJ20128), TBX2, and an EST (T02811.1).
We confirmed the presence of this distinct 17q23 amplicon in
two other breast cancer cell lines. We also detected a more
proximal region of amplification in the primary breast tumor
sample but the ratio of amplification in the proximal amplicon
was around two- fold with no significant overexpression,
whereas overexpression was more than five- fold in the distal
TBX2 amplification region. This suggests that the genes in
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the proximal 17q23 region are unlikely candidates for
potential oncogenes in this specific primary breast tumor
sample.
Identification of the distinct amplicons confirms the
importance of the present candidate genes including TBX2,
RPS6KB1, and MUL and suggests potential coactivity of
different amplification targets. MUL (Mulibrey nanism) is an
interesting gene that encodes a protein with a RING-B-box-
Coiled coil domain of zinc finger proteins. This group of
proteins is involved in the diverse cellular functions such as
developmental patterning and oncogenesis as 4% of
patients with Mulibrey nanism develop Wilm’s tumor [20].
In addition, we report here amplification and overexpression
of ESTs that are also potential oncogene candidates. As
17q23 is a gene-rich region and there are some ESTs not yet
well -characterized, it will be interesting to further study these
ESTs to understand their potential roles in cancer progres-
sion. For example, FLJ20128 is a protein of unknown
function with no known domains or homology to any genes
in the databases and it is significantly amplified and overex-
pressed in three breast cancer cell lines and the primary
breast tumor sample.
It is also possible that there are other small amplicons in
the region. We have only screened a small subset of a
very gene- rich region. Thus, as more sequence becomes
available, the boundaries and the sizes of the amplicons
reported here and other possible new small amplicons will
be identified more precisely. In addition, there are
orientation discrepancies of markers within the contigs
between the literature [17] and the databases. This
discrepancy is due to lack of sequenced overlapping
contigs in the databases. Thus, as the gaps between the
17q23 contigs are sequenced, the discrepancy will be
resolved. We present the markers in the order defined in
the recent physical map of the region [17]. This discrep-
ancy does not affect the results reported here because
only orientation of markers in contigs might be changed
(NT_001445), but not the genomic regions of amplification
and overexpression.
In summary we have delineated two distinct amplicons on
17q23 in breast cancer cell lines. The presence of two critical
amplicons suggests that the known strong candidate genes
or as of yet uncharacterized genes in the region might be
functioning together in the complex process of tumor
progression. Further analysis on primary tumors is also
required to reveal the significance of these amplifications and
functional analyses will determine the roles and interactions
of overexpressed candidate oncogenes in these amplicons
on 17q23.
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